Kiniksa Pharmaceuticals International (KNSA) Corporate presentation summary

Strategic focus and portfolio highlights

• Prioritizing novel therapies for cardiovascular diseases, especially recurrent pericarditis, with a strong foundation in ARCALYST and advancing clinical assets like KPL-387 and KPL-1161.

• ARCALYST has generated ~$1.5B net revenue since launch, with 2026 revenue guidance of $900–$920M and only ~18% penetration into the multiple recurrence population.

• KPL-387, a wholly owned IL-1 antagonist, is in Phase 2/3 trials for recurrent pericarditis, with Phase 2 data expected in 2H 2026; KPL-1161 Phase 1 to start by end of 2026.

• Financial strength is underpinned by $414M in year-end 2025 cash reserves and a cash flow positive operating plan.

ARCALYST commercial performance and market dynamics

• ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis, with orphan drug exclusivity and a 50/50 profit split with Regeneron.

• Q4 2025 net revenue reached $202.1M, representing ~65% YoY growth, with >4,150 prescribers and ~1,200 repeat prescribers.

• Penetration into the multiple recurrence population is ~18%, with increasing use in first recurrence patients and strong payer approval.

• ARCALYST list price is $25,158/month, with robust patient support programs and a largely commercial payer mix (~65%).

• 2026 net product sales are expected to reach $900–$920M, up from $677.5M in 2025.

Clinical and real-world evidence

• ARCALYST reduced pericarditis recurrence risk by 96% in pivotal Phase 3 RHAPSODY trial; long-term extension data show sustained benefit with 97% recurrence-free rate beyond 18 months.

• Real-world data confirm a 99.5% reduction in recurrence rates, independent of line of therapy at initiation.

• ARCALYST monotherapy provided long-term prevention of recurrence over three years, with 96% of patients recurrence-free.

• ACC clinical guidance now recommends IL-1 pathway inhibition as second-line therapy after NSAIDs/colchicine.